Clinical consequences of primary CMV infection after renal transplantation : a case–control study
Abstract The impact of primary cytomegalovirus infection (pCMV) on renal allograft function and histology is controversial. We evaluated the influence on incidence of acute rejection, allograft loss, allograft function and interstitial fibrosis/tubular atrophy (IF/TA). Retrospective case–control study, recipients transplanted between 2000 and 2014. Risk of acute rejection and allograft loss for those who experienced pCMV infection compared with those who did not, within an exposure period of two months after transplantation. Besides, its influence on allograft function and histology at one to three years after transplantation. Of 113 recipients experienced pCMV infection, 306 remained CMV seronegative. pCMV infection in the exposure period could not be proven as increasing the risk for acute rejection [HR = 2.18 (95% CI 0.80–5.97) P = 0.13] or allograft loss [HR = 1.11 (95%CI 0.33–3.72) P = 0.87]. Combination of pCMV infection and acute rejection posed higher hazard for allograft loss than acute rejection alone [HR = 3.69 (95% CI 1.21–11.29) P = 0.02]. eGFR(MDRD) values did not significantly differ at years one [46 vs. 50], two [46 vs. 51] and three [46 vs. 52]. No association between pCMV infection and IF/TA could be demonstrated [OR = 2.15 (95%CI 0.73–6.29) P = 0.16]. pCMV infection was not proven to increase the risk for acute rejection or allograft loss. However, it increased the risk for rejection‐associated allograft loss. In remaining functioning allografts, it was not significantly associated with decline in function nor with presence of IF/TA..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Transplant international - 33(2020), 9, Seite 1116-1127 |
| Beteiligte Personen: |
Singh, Ramandeep [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd |
|---|
| Umfang: |
12 |
|---|
| doi: |
10.1111/tri.13667 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY014012855 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY014012855 | ||
| 003 | DE-627 | ||
| 005 | 20230308023533.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230221s2020 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/tri.13667 |2 doi | |
| 028 | 5 | 2 | |a TRI_TRI13667.xml |
| 035 | |a (DE-627)WLY014012855 | ||
| 035 | |a (WILEY)TRI13667 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.65 |2 bkl | ||
| 084 | |a 44.87 |2 bkl | ||
| 100 | 1 | |a Singh, Ramandeep |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical consequences of primary CMV infection after renal transplantation |b a case–control study |
| 264 | 1 | |c 2020 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd | ||
| 520 | |a Abstract The impact of primary cytomegalovirus infection (pCMV) on renal allograft function and histology is controversial. We evaluated the influence on incidence of acute rejection, allograft loss, allograft function and interstitial fibrosis/tubular atrophy (IF/TA). Retrospective case–control study, recipients transplanted between 2000 and 2014. Risk of acute rejection and allograft loss for those who experienced pCMV infection compared with those who did not, within an exposure period of two months after transplantation. Besides, its influence on allograft function and histology at one to three years after transplantation. Of 113 recipients experienced pCMV infection, 306 remained CMV seronegative. pCMV infection in the exposure period could not be proven as increasing the risk for acute rejection [HR = 2.18 (95% CI 0.80–5.97) P = 0.13] or allograft loss [HR = 1.11 (95%CI 0.33–3.72) P = 0.87]. Combination of pCMV infection and acute rejection posed higher hazard for allograft loss than acute rejection alone [HR = 3.69 (95% CI 1.21–11.29) P = 0.02]. eGFR(MDRD) values did not significantly differ at years one [46 vs. 50], two [46 vs. 51] and three [46 vs. 52]. No association between pCMV infection and IF/TA could be demonstrated [OR = 2.15 (95%CI 0.73–6.29) P = 0.16]. pCMV infection was not proven to increase the risk for acute rejection or allograft loss. However, it increased the risk for rejection‐associated allograft loss. In remaining functioning allografts, it was not significantly associated with decline in function nor with presence of IF/TA. | ||
| 700 | 1 | |a Peters‐Sengers, Hessel |4 aut | |
| 700 | 1 | |a Remmerswaal, Ester B.M. |4 aut | |
| 700 | 1 | |a Yapici, Unsal |4 aut | |
| 700 | 1 | |a Pant, Karlijn A. M .I. |4 aut | |
| 700 | 1 | |a Weerd, Neelke C. |4 aut | |
| 700 | 1 | |a Roelofs, Joris J. T. H. |4 aut | |
| 700 | 1 | |a Lier, René A. W. |4 aut | |
| 700 | 1 | |a Bemelman, Fréderike J. |4 aut | |
| 700 | 1 | |a Florquin, Sandrine |4 aut | |
| 700 | 1 | |a ten Berge, Ineke J. M. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplant international |d Lausanne : Frontiers Media, 1988 |g 33(2020), 9, Seite 1116-1127 |w (DE-627)WLY014009943 |w (DE-600)1463183-0 |x 14322277 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2020 |g number:9 |g pages:1116-1127 |g extent:12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.65 |q ASE |
| 936 | b | k | |a 44.87 |q ASE |
| 951 | |a AR | ||
| 952 | |d 33 |j 2020 |e 9 |h 1116-1127 |g 12 | ||